ATE107861T1 - Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids. - Google Patents

Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.

Info

Publication number
ATE107861T1
ATE107861T1 AT87113709T AT87113709T ATE107861T1 AT E107861 T1 ATE107861 T1 AT E107861T1 AT 87113709 T AT87113709 T AT 87113709T AT 87113709 T AT87113709 T AT 87113709T AT E107861 T1 ATE107861 T1 AT E107861T1
Authority
AT
Austria
Prior art keywords
lymphocytes
activated
aids
aids virus
pharmaceutical composition
Prior art date
Application number
AT87113709T
Other languages
English (en)
Inventor
Shiu-Lok Hu Ph D
Joyce Zarling
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Application granted granted Critical
Publication of ATE107861T1 publication Critical patent/ATE107861T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT87113709T 1986-09-19 1987-09-18 Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids. ATE107861T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90944786A 1986-09-19 1986-09-19

Publications (1)

Publication Number Publication Date
ATE107861T1 true ATE107861T1 (de) 1994-07-15

Family

ID=25427241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87113709T ATE107861T1 (de) 1986-09-19 1987-09-18 Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.

Country Status (5)

Country Link
EP (1) EP0260714B1 (de)
JP (2) JPS63119428A (de)
AT (1) ATE107861T1 (de)
DE (1) DE3750151T2 (de)
ES (1) ES2056054T3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002277A2 (en) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
WO1992004462A1 (en) * 1990-09-06 1992-03-19 Immulogic Pharmaceutical Corporation Pathogen-specific ctl therapy
DE4422020A1 (de) * 1993-07-29 1995-02-02 Bernhard Heising Pharmazeutische Zusammensetzung
AU7386094A (en) * 1993-07-29 1995-02-28 Bernhard Heising T-lymphocyte-containing pharmaceutical composition for treating infections
ES2203782T3 (es) * 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
WO2010104836A1 (en) * 2009-03-09 2010-09-16 Tvax Biomedical, Llc Infectious disease cellular immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587512T2 (de) * 1984-10-18 1993-12-02 Centre Nat Rech Scient Hüllenantigene vom menschlichen Immunodefizienz-Virus und deren Verwendungen.
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR2593190B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida

Also Published As

Publication number Publication date
ES2056054T3 (es) 1994-10-01
DE3750151T2 (de) 1994-12-01
JPS63119428A (ja) 1988-05-24
EP0260714A2 (de) 1988-03-23
DE3750151D1 (de) 1994-08-04
EP0260714B1 (de) 1994-06-29
EP0260714A3 (en) 1988-08-24
JPH08308563A (ja) 1996-11-26

Similar Documents

Publication Publication Date Title
ITRM910292A0 (it) Procedimento per la preparazione di elastomeri mediante l'impiego di polioli o poliammine ad elevato peso molecolare.
IT1055354B (it) Ventro ceramica biocompatibile e utilizzazione di questo vetro per la fabbricazione di protesi ossee
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
DE3677897D1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
EP0219076A3 (en) Sustained release composition
PL328003A1 (en) Modulation of cytokin th 1/th 2 expression by means of ribavirin and ribavirin analoques in t lymphocytes
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
DK169986A (da) Antigen beslaegtet med glycoproteinet i aids-virus, isaer en praekursor for glycoproteinet, og fremgangsmaade til fremstilling af et saadant antigen
DK208987D0 (da) Polypeptider og antistoffer, som er karakteristiske for papillomvirus, og deres anvendelse ved diagnostiske metoder og i vacciner
ATE107861T1 (de) Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
ES557292A0 (es) Procedimiento para la preparacion de un componente activo inmovilizado destinado al diagnostico.
NO880935D0 (no) Fremgangmsaate for paavisning av hiv eller annet virus med lignende klinisk virkning.
ES546974A0 (es) Un procedimiento de eliminacion del virus lav.
PT87004A (pt) Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
IE781308L (en) Benzylpyrimidines
GB2185478B (en) Novel e-valerolactam, pharmacologically active compositions thereof, processes for the preparation thereof and their medical use
ES2053601T3 (es) Agentes de biocontrol fundidos.
Lueders Exogen induced disease of oral mucous membrane.
BR9909350A (pt) Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico
Averitt Rebuilding the immune system
De Sena et al. Epidemiological and clinic review of 2131 patients affected with an infection of oro-fecal transmission.
Tauris et al. Lymphocyte immunoglobulin secretion during short-term treatment with cephalosporins in vivo and in vitro: effects on plaque-forming cell response of human peripheral blood lymphocytes
GB2185479B (en) Novel amides, pharmacologically active compositions thereof, processes for the preparation thereof and their medical use
ATE27772T1 (de) Pharmazeutische zusammensetzungen zur bekaempfung des widerstands von bakterien enthaltenden anaerobien.

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee